OBJETIVO: Este estudo comparou parâmetros antropométricos e de resistência à insulina de indivíduos sem e com síndrome metabólica (SM), subestratificados pela presença de anormalidades glicêmicas. SUJEITOS E MÉTODOS: Foram incluídos 454 indivíduos (66% mulheres, 54% brancos), sendo 155 alocados para o grupo 1 (sem SM, sem anormalidade glicêmica), 32 para o grupo 2 (sem SM, com anormalidade glicêmica), 104 no grupo 3 (com SM, sem anormalidade glicêmica) e 163 no grupo 4 (com SM e anormalidade glicêmica). Os grupos foram comparados por ANOVA. RESULTADOS: Os grupos com SM (3 e 4) apresentaram os piores perfis antropométrico e lipídico; no grupo 2, apesar de glicemias significantemente mais elevadas, as médias das variáveis antropométricas e lipídicas não diferiram do grupo 1. Os maiores valores médios de HOMA-IR foram encontrados nos grupos com SM, enquanto o grupo 2 apresentou o menor HOMA-β. A trigliceridemia foi a variável metabólica com coeficientes de correlação mais elevados com a antropometria. Porém, as correlações mais fortes foram da circunferência da cintura (r = 0,503) e da razão cintura-altura (r = 0,513) com o HOMA-IR (p < 0,01). CONCLUSÃO: Nossos achados revelam que, em amostra da população brasileira, qualquer das medidas antropométricas identifica indivíduos com SM, mas não parece capaz de diferenciar aqueles com distúrbio glicêmico. Reforçamos a relação mais forte das medidas de adiposidade central com resistência à insulina, sugerindo utilidade da razão cintura-altura. É possível que componente autoimune contribua para o comprometimento do metabolismo glicídico dos indivíduos do grupo 2.

No abstract

HPV is associated with cervical cancer and plays a crucial role in tumor formation. Apoptosis is regulated by different pathways involving genes that either promote (BCL2 gene) or inhibit (BAX gene) cell death. Our goal was to determine whether the BCL2-938C>A (rs2279115) and BAX-248G>A (rs4645878) single nucleotide polymorphisms (SNPs) are associated with squamous intraepithelial neoplasia (SIL) risk, and whether their phenotypic expression was impaired in these lesions. Two hundred and thirty-one cases showing SIL were classified as low SIL (LSIL, n = 101) or high SIL (HSIL, n = 130), and control subjects (n = 266) with no gynecologically proven SIL were recruited. No statistical difference in the genotype and allelic frequency of the BCL-2-938C>A polymorphism was observed among the groups. BCL2-938C/A and A/A homozygotes carriers had higher distribution of BCL-2-expressing cells in stroma in the SIL group. BCL2 mRNA-expression was not correlated with BCL2-938C>A SNPs in both groups. We did find a strong association of the BAX GG genotype and risk for SIL. No difference was observed between LSIL and HSIL groups. In BAX-248G/A and A/A homozygote carriers, the number of BAX-expressing cells was lower the epithelium area in SIL. However, mRNA expression was higher in SIL patients than in the control group. In conclusion, our data provide evidence that allele G carriers in the BAX-248G>A promoter SNP may influence the development of SIL. However, this genotype does not influence the SIL outcome. Additionally, we suggest a possible role of HPV infection in the inhibition of the expression of BAX protein, decreasing cell death, and favoring cervical carcinogenesis.

The interplay between cervical cancer (CC) and immune cells, mainly intratumoral lymphocytes, has a pivotal role in carcinogenesis. In this context, we evaluated the distribution of CD45RA+ and CD45RO+ cells as well as CCR6+ and CCL20+ cells in intraepithelial (IE) and marginal stroma (MS) areas from cervical intraepithelial neoplasia (CIN) I–III, and CC as ‘immunoscore’ for HPV-induced CC outcome. We observed increased CD45RA+ and CD45RO+ cells distribution in IE and MS areas in the CC group compared to CIN groups and healthy volunteers. Interestingly, there is a remarkable reduction of CCL20+ expressing cells distribution according to lesion severity. The CC group had a significant decrease in CCL20+ and CCR6+-expressing cells distribution in both IE and MS areas compared to all groups. Using the ‘immunoscore’ model, we observed an increased number of women presenting high CD45RA+/CD45RO+ and low CCL20+/CCR6+ ‘immunoscore’ in the CC group. Our results suggested a pattern in cervical inflammatory process with increasing CD45RA+/CD45RO+, and decreasing CCL20+/CCR6+ expression in accordance with CIN severity. Taken together, these markers could be evaluated as ‘immunoscore’ predictors to CC response. A more comprehensive analysis of longitudinal studies should be conducted to associate CD45RA+/CD45RO+ and CCL20+/CCR6+ ‘immunoscore’ to CC progression and validate its value as a prognosis method.

TNF-α is involved in HPV infection control by triggering cell signaling through binding in specific receptors TNFR1 and TNFR2. Genetic polymorphisms in these receptors may influence TNF-α signaling. Herein, we investigated TNFR1 rs767455 and rs2234649 single nucleotide polymorphisms, and TNFR1 protein expression in cervical squamous intraepithelial lesions (SIL) to identify their role in cervical pre-malignant development. SIL patients ( n = 179) and healthy volunteers ( n = 227) were enrolled for TNFR1 genotyping analysis by PCR-RFLP in blood samples and TNFR1 protein expression in cervical tissue by immunohistochemistry. No statistical differences regard genotypes and allelic frequencies for both polymorphisms were observed. Cervical TNFR1-expressing cells were rare in epithelium and basal layer regardless the groups. However, a progressive increase in infiltrating cells was observed in the stromal area, mainly in high SIL (HSIL) group compared to low SIL (LSIL, p < 0.001) and control ( p < 0.001) groups. TNFR1-expressing cells frequency was higher in TNFR1 rs767455AG/GG ( p < 0.001), and in rs2234649AA ( p < 0.001) genotypes carries in HSIL subgroup. These data indicated that TNFR1-expression is abrogated in cervical epithelium, where HPV-induced pre-malignant lesion occurs, increasing its frequency in inflammatory cells in stroma, and is genetically controlled by TNFR1 rs767455AG /GG and rs234649AA genotypes. These biomarkers may be useful to identify cervical precancerous lesions progression.

Cervical cancer (CC) is the fourth most common type of cancer among women and is responsible for about 8% of female cancer deaths worldwide. Understanding how the tumor microenvironment behaves is essential to realize the carcinogenic process, and thus infer possible prognostic biomarkers in the CC development. One of the prognostic factors that has aroused interest in recent years is the increased expression of metalloproteinases (MMPs) in tumor tissues, which is associated with tumor growth and metastasis, and recurrence of degradation of extracellular matrix (ECM) components in tissues of different tumors. Thus, our objective is to evaluate the in situ distribution of MMPs+ cells (MMP-2, -7, -9), as well as TIMP-2+, EphA2+ and EfrinA1+ cells in intraepithelial (IE) and marginal stroma (MS) areas using the technique of immunohistochemistry and immunoscore analysis in low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively) and CC. We observed in MS, a high distribution of MMPs+ (-2, -7 and − 9), TIMP2+ and EPHA2+ cells in the HSIL and CC group compared to the control. Regarding IE, we observed this same pattern, except in EPHA2 where there was a decrease in the positive cells distribution in CC compared to control and LSIL. Regarding the “immunoscore”, from 15 possible profiles, we found statistical differences in only 9 (MMP-2+/MMP-9+, MMP-2+/EphA2+, MMP-7+/MMP-9+, MMP- 7+/TIMP-2+, MMP-7+/EphA2+, MMP-9+/EphA2+, TIMP-2+/EphA2+, TIMP-2+/EphrA1+ and EphA2+/EphrA1+) when the groups were compared. However, only the MMP-7+/MMP-9+ profile can be used as a prognostic factor for the development of CC and the MMP-7+/EphA2+, MMP-9+/EphA2+ and TIMP-2+/EphA2+ profiles may be related to the development of precancerous lesions. A more comprehensive review of longitudinal studies should be performed to link these “immunoscores” to CC progression and validate their value as a prognostic method.